Using logistic-regression analyses, none of the baseline factors examined, including age, gender, body mass index, type of IBD and its phenotype, prior IBD therapies, endoscopic severity, or baseline C-reactive protein, was found to be predictive of increased risk of surgery among the elderly patients on vedolizumab. Here, CRP is linked to inflammatory bowel disease.